We previously reported a dose-finding and phase II trial of the TI-CE regimen (paclitaxel [T] plus ifosfamide [I] followed by high-dose carboplatin [C] plus etoposide [E] with stem-cell support) in ...
Hospital records were reviewed and baseline, transplant, response and survival data collected. Survival data was censored as of 30 June 2015. Carboplatin was dosed according to a target area under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results